Gyros continues positive trend in 2011
North American market saw revenue growth of 100% compared to the same period in 2010
Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that sales are showing a positive trend similar to that seen throughout 2010. Major biopharmaceutical companies continued to demonstrate their confidence in the Gyros immunoassay platform, with existing accounts investing in additional Gyrolab™ workstations at different sites on both sides of the Atlantic. The North American market, containing many of the key players involved in global efforts to develop novel biotherapeutics, had a particularly strong start with a revenue growth of 100% compared to the same period in 2010. The number of service providers, such as CRO’s, implementing Gyrolab workstations into their projects also increased.
Commenting on the announcement, Erik Walldén, President and Chief Executive Officer of Gyros AB, said: “This positive trend confirms that our immunoassay platform is increasingly regarded as an established standard for many time-critical workflows in biotherapeutic development processes. This recognition is also reflected by the interest shown in our annual Gyrolab seminars, held in the USA and Europe, which attract scientists from across the industry.” Mr. Walldén continued, “Our growing installed base means significant growth in orders for consumables, especially our unique Gyrolab CDs in which the immunoassay steps take place under control of the workstation. Moving forward, Gyros is in an excellent position to set the industry standard for transforming the performance of immunoassays wherever they are utilized within the biopharmaceutical industry.”
The Company’s open, automated platform supports time-critical workflows in the biopharmaceutical industry, boosting productivity and cutting time to result. Automatically running immunoassays at nanoliter scale not only ensures faster development times, but also saves labor, sample and reagents. Assays are readily transferred downstream into GxP environments and between different sites, greatly facilitating collaborations between biopharmaceutical companies and their service providers. Having established the platform in the USA and Europe, Gyros is now focused on building awareness in Asia Pacific, where the Company recently announced that it has appointed a network of distributors.
For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: firstname.lastname@example.org / email@example.com
Notes to editors:
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.